Chemical Property of Belinostat
Chemical Property:
- Refractive Index:1.667
- PKA:8.31±0.10(Predicted)
- PSA：103.88000
- Density:1.428 g/cm3
- LogP:3.55070
- Storage Temp.:Amber Vial, Refrigerator, Under inert atmosphere
- Solubility.:DMSO (Slightly), Methanol (Slightly)
- XLogP3:1.7
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:5
- Rotatable Bond Count:5
- Exact Mass:318.06742811
- Heavy Atom Count:22
- Complexity:492
- Purity/Quality:
-
99%, *data from raw suppliers
Belinostat(PXD-101) *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Antineoplastic Agents
- Canonical SMILES:C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO
- Isomeric SMILES:C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO
- Recent ClinicalTrials:Tremelimumab, Durvalumab, and Belinostat for the Treatment of ARID1A Mutated Metastatic or Unresectable, Locally Advanced Urothelial Carcinoma
- Recent EU Clinical Trials:Randomised Open Label Adaptive Phase III trial of addition of Belinostat to chemotherapy in patients with locally advanced potentially resectable Thymic Epithelial Tumors (TET)
-
Description
Belinostat is a drug which was developed by Spectrum Pharmaceuticals
and is currently marketed by Onxeo as Beleodaq?. The
drug, which received fast track designation by the United States
Food and Drug Administration (US FDA) and was approved for
the treatment of hematological malignancies and solid tumors
associated with peripheral T-cell lymphoma (PTCL) in 2014, is a
histone deacetylase (HDAC) inhibitor and is the third such treatment
to receive accelerated approval for PTCL, the others being
vorinostat (Zolinza?) and pralatrexate (Folotyn?). Although belinostat
was not yet approved in Europe as of August 2014, the
compound exhibits a safety profile considered to be acceptable
for HDAC inhibitors–less than 25% of patients reported adverse
effects and these most frequently were nausea, fatigue, pyrexia,
anemia, and emesis.
-
Uses
Belinostat is a novel histone deacetylase 3 selective inhibitor, which protects the β cells from cytokine-induced apoptosis.
